Literature DB >> 17594053

Construction of double suicide genes system controlled by MDR1 promoter with targeted expression in drug-resistant glioma cells.

Yuan Zhang1, Cheng-wei Wang, Zhi-gang Wang, Dao-xin Ma, Shun Pan, Shu-gan Zhu, Feng Li, Bo Wang.   

Abstract

The multiple drug resistance protein (MDR1) is frequently overexpressed in human glioma. The aim of this study is to clone the MDR1 promoter from C6/ADR, construct the double suicide genes expressive vector controlled by MDR1 promoter, and explore its targeted expression in C6/ADR cells. MDR1 promoter from C6/ADR genomic DNA, which was linked with T vector, was amplified by using Polymerase chain reaction (PCR). After cut by NdeI and HindIII, MDR1 promoter was cloned into pcDNA3-TK (thymidine kinase) plasmid. The cytosine deaminase (CD) gene from pcDNA3-CD-TK plasmid was directly cloned into the above vector to construct pcDNA3-MDR1-promoter-CD-TK vector. Then this vector was transfected into C6 and C6/ADR cells respectively by liposome. After selection by G418, the tumor cell lines were stably established. Then these cell lines were examined through PCR and RT-PCR to respectively detect the integration and expression of TK and CD genes. The results showed the length and sequence of MDR1 promoter amplified by PCR were confirmed by DNA sequencing. The pcDNA3-MDR1-promoter-CD-TK expression vectors were constructed successfully. PCR indicated the double suicide genes were integrated into C6 and C6/ADR cells. RT-PCR revealed that CD and TK genes expressed in C6/ADR/CD-TK cells, whereas not in C6/CD-TK cells. In conclusions, construction of expressive vector containing double suicide genes controlled by MDR1 promoter with targeted expression in C6/ADR will provide a sound basis for targeted gene therapy for multidrug resistance (MDR) glioma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17594053     DOI: 10.1007/s11060-007-9431-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  31 in total

1.  Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line.

Authors:  B Ogretmen; A R Safa
Journal:  Biochemistry       Date:  2000-01-11       Impact factor: 3.162

2.  Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1.

Authors:  J Sampath; D Sun; V J Kidd; J Grenet; A Gandhi; L H Shapiro; Q Wang; G P Zambetti; J D Schuetz
Journal:  J Biol Chem       Date:  2001-08-01       Impact factor: 5.157

Review 3.  Cellular mechanisms of multidrug resistance of tumor cells.

Authors:  A A Stavrovskaya
Journal:  Biochemistry (Mosc)       Date:  2000-01       Impact factor: 2.487

4.  Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies.

Authors:  N Kartner; D Evernden-Porelle; G Bradley; V Ling
Journal:  Nature       Date:  1985 Aug 29-Sep 4       Impact factor: 49.962

5.  Chromosomal modifications of a rat glioblastoma cell line during the acquisition and reversal of doxorubicin resistance.

Authors:  D Montaudon; M N Benchekroun; D Londos-Gagliardi; J Robert
Journal:  Anticancer Res       Date:  1990 Nov-Dec       Impact factor: 2.480

Review 6.  Targeted therapy for malignant gliomas.

Authors:  Andrew P Morokoff; Ulrike Novak
Journal:  J Clin Neurosci       Date:  2004-11       Impact factor: 1.961

7.  Selection of a new multidrug resistant cell line from Friend leukemia cells by short and cyclic exposures to high concentrations of daunorubicin.

Authors:  V Abbadessa; M Tolomeo; M Luparello; R Perricone; A Cajozzo; L Dusonchet; V Candiloro; L Crosta; L Rausa
Journal:  Haematologica       Date:  1992 Mar-Apr       Impact factor: 9.941

8.  An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene.

Authors:  K H Choi; C J Chen; M Kriegler; I B Roninson
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

9.  Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma.

Authors:  Peter Hau; Klaus Fabel; Ulrike Baumgart; Petra Rümmele; Oliver Grauer; Annekatrin Bock; Christopher Dietmaier; Wolfgang Dietmaier; Jörg Dietrich; Christine Dudel; Franz Hübner; Tanya Jauch; Elisabeth Drechsel; Ingo Kleiter; Cäcile Wismeth; Anton Zellner; Alexander Brawanski; Andreas Steinbrecher; Jörg Marienhagen; Ulrich Bogdahn
Journal:  Cancer       Date:  2004-03-15       Impact factor: 6.860

10.  Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi.

Authors:  C R Fairchild; J A Moscow; E E O'Brien; K H Cowan
Journal:  Mol Pharmacol       Date:  1990-06       Impact factor: 4.436

View more
  2 in total

1.  Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma.

Authors:  Forrest M Kievit; Omid Veiseh; Chen Fang; Narayan Bhattarai; Donghoon Lee; Richard G Ellenbogen; Miqin Zhang
Journal:  ACS Nano       Date:  2010-08-24       Impact factor: 15.881

2.  Lentivirus-mediated CD/TK fusion gene transfection neural stem cell therapy for C6 glioblastoma.

Authors:  Jian Niu; Chunyang Xing; Chao Yan; Hao Liu; Yuqiong Cui; Haisheng Peng; Yingli Chen; Dianjun Li; Chuanlu Jiang; Nannan Li; Haicheng Yang
Journal:  Tumour Biol       Date:  2013-07-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.